Posted inBiotechnology
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
After former Legend Biotech CEO Ying Huang, Ph.D., left the company suddenly in July, Legend has found its permanent CEO,…
Posted inGenetics
Sartorius and NIBRT Partner on Intensified and Continuous Bioprocessing Training Center
Cell culture [dra_schwartz/Getty Images] Sartorius and the Ireland-based National Institute for Bioprocessing Research and Training (NIBRT) are partnering to establish…
Posted inGenetics
Mithrl Raises $20M to Expand Deployment of Its Biomedical World Model Across Biopharma
Credit: Yuichiro Chino / Moment / Getty Images Vivek Adarsh’s reasons for founding Mithrl are quite personal. About 15 years…
Posted inBiotechnology
Goa Therapeutics launches with ‘immeasurably huge’ vision of creating Narcan for alcohol
A new biotech has sprung out of stealth with a bold vision to develop the “greatest therapeutic of all time”—a…
Posted inResearch
DPHARM: How to address the clinical trial enrollment crisis?
Clinical trials are facing an enrollment crisis. Around 80% of trials don’t meet their enrollment timelines, and fewer than 5%…
Posted inBiotechnology
After one failed acquisition attempt, Lisata finds lifeline in Marea merger
After a failed merger that led to massive layoffs and a lawsuit, solid tumor biotech Lisata Therapeutics has found a…
Posted inBiotechnology
Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive
Roche is paying Dualitas Therapeutics $36.5 million upfront to screen over 300,000 novel bispecific combinations in search of new treatments…
Posted inBiotechnology
North Immunology goes public via reverse merger as eczema drug heads toward clinic
North Immunology has decided its path to taking an atopic dermatitis drug into the clinic involves going public via a…
Posted inBiotechnology
SK pens $315M pact with fellow South Korean company for Parkinson’s prospect
SK Biopharmaceuticals has added a second preclinical Parkinson’s disease therapy to its pipeline courtesy of a $314.8 million biobucks deal…
Posted inBiotechnology
Longeveron’s phase 2b stem cell flop spurs cost cutting, exploration of ‘all options’
A phase 2b study of Longeveron’s stem cell therapy in a pediatric heart disease has missed its primary endpoint, prompting…